Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the united states for the diagnosis and treatment of dyslipidemia - Data from National Health and Nutrition Examination Survey 1999 to 2002

被引:65
作者
Keevil, Jon G. [1 ]
Cullen, Michael W. [1 ]
Gangnon, Ronald [1 ]
McBride, Patrick E. [1 ]
Stein, James H. [1 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA
关键词
cardiovascular diseases; cholesterol; guidelines; lipids; risk factors;
D O I
10.1161/CIRCULATIONAHA.106.645473
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Updated guidelines from the National Cholesterol Education Program Adult Treatment Panel III stratify patients into 5 groups of coronary heart disease (CHD) risk that determine intensity of lipid-lowering therapy. The present study assesses the distribution of low-density lipoprotein cholesterol (LDL-C) in the United States across the 5 groups of CHD risk as defined in the updated guidelines. Methods and Results-Subjects included 7399 individuals 20 to 79 years of age in the 1999 to 2002 National Health and Nutrition Examination Survey representing 171 million individuals in the United States. CHD risk, LDL-C levels, and goal achievement were determined per Adult Treatment Panel III guidelines. CHD risk assessment incorporated a medical condition review, risk factor summation, and Framingham Risk Score calculation. Percentages were weighted to represent population estimates, and SEs were adjusted for the survey design. The distribution of individuals by CHD risk included 61.1% at lower risk, 10.6% at high risk, and 5.7% at very high risk. From Adult Treatment Panel III criteria, only 5.4% of the population was at "intermediate" risk. Two thirds (66.3%) met their Adult Treatment Panel III-defined LDL-C goal. Of those at high and very high risk, 23% and 26%, respectively, met the goal of LDL-C < 100 mg/dL, whereas only 3.1% and 4.6% had an LDL-C < 70 mg/dL (or non-high-density lipoprotein C < 100 mg/dL). Conclusions-Most adult US residents are at lower 10-year CHD risk and meet risk-adjusted LDL-C goals. However, large portions of the high-risk population are undertreated. The commonly described population at intermediate risk is small. A novel method of identifying patients who might benefit from additional testing to determine their treatment strategy is provided.
引用
收藏
页码:1363 / 1370
页数:8
相关论文
共 24 条
[11]  
Genuth S, 2003, DIABETES CARE, V26, P3160
[12]  
Greenland P, 2000, CIRCULATION, V101, P723
[13]   Improving coronary heart disease risk assessment in asymptomatic people - Role of traditional risk factors and noninvasive cardiovascular tests [J].
Greenland, P ;
Smith, SC ;
Grundy, SM .
CIRCULATION, 2001, 104 (15) :1863-1867
[14]   Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [J].
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, R ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Cleeman, JI ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ ;
Keller, SA ;
Jehle, AJ .
CIRCULATION, 2002, 106 (25) :3143-3421
[15]   Diagnosis and management of the metabolic syndrome - An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [J].
Grundy, SM ;
Cleeman, JI ;
Daniels, SR ;
Donato, KA ;
Eckel, RH ;
Franklin, BA ;
Gordon, DJ ;
Krauss, RM ;
Savage, PJ ;
Smith, SC ;
Spertus, JA ;
Costa, F .
CIRCULATION, 2005, 112 (17) :2735-2752
[16]   Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [J].
Grundy, SM ;
Cleeman, JI ;
Merz, CNB ;
Brewer, HB ;
Clark, LT ;
Hunninghake, DB ;
Pasternak, RC ;
Smith, SC ;
Stone, NJ .
CIRCULATION, 2004, 110 (02) :227-239
[17]   Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data [J].
Jacobson, TA ;
Griffiths, GG ;
Varas, C ;
Gause, D ;
Sung, JCY ;
Ballantyne, CM .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (09) :1361-1369
[18]   The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men [J].
Lakka, HM ;
Laaksonen, DE ;
Lakka, TA ;
Niskanen, LK ;
Kumpusalo, E ;
Tuomilehto, J ;
Salonen, JT .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (21) :2709-2716
[19]  
Linfante A, 2004, CIRCULATION, V110, P664
[20]   Markers of inflammation and cardiovascular disease application to clinical and public health practice - A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association [J].
Pearson, TA ;
Mensah, GA ;
Alexander, RW ;
Anderson, JL ;
Cannon, RO ;
Criqui, M ;
Fadl, YY ;
Fortmann, SP ;
Hong, Y ;
Myers, GL ;
Rifai, N ;
Smith, SC ;
Taubert, K ;
Tracy, RP ;
Vinicor, F .
CIRCULATION, 2003, 107 (03) :499-511